Search Result

Results for "

peptic secretion

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Bacterial (5) Histamine Receptor (2) Isotope-Labeled Compounds (1) mAChR (3) Proton Pump (6)
By Research Areas:	Cancer (4) Endocrinology (4) Infection (3) Inflammation/Immunology (4) Metabolic Disease (4) Neurological Disease (1)

Inhibitors & Agonists

Fluorescent Dye

Biochemical Assay Reagents

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-17037

Pirenzepine dihydrochloride 1 Publications Verification LS 519; Pirenzepin dihydrochloride; Gastrozepin dihydrochloride	mAChR	Metabolic Disease Cancer
Pirenzepine (LS 519) dihydrochloride is a selective M1 mAChR (muscarinic acetylcholine receptor) antagonist. Pirenzepine dihydrochloride reduces gastric acid secretion and reduces muscle spasm, can be used in peptic ulcers research. Pirenzepine dihydrochloride shows anti-proliferative activity to cancer cells .

HY-129415

Esaprazole Hexaprazole	Others	Others
Esaprazole (Hexaprazole) is an antiulcer agent that has the effect of promoting the healing of peptic ulcer. Esaprazole can inhibit the secretion of gastric acid and pepsin .

HY-160979

Bisfentidine DA-5047	Histamine Receptor	Others Endocrinology
Bisfentidine is an H2 receptor antagonist, Bisfentidine can block the H2 receptor on the cells of the stomach wall, and reduce the secretion of stomach acid. Bisfentidine binds to cytochrome P-450 in liver microsomes and affects drug metabolism. Bisfentidine can be used in the study of metabolic processes of drugs, lipid peroxidation processes and peptic ulcers diseases .

HY-B1475

Anisotropine bromide Octatropine bromide	mAChR	Neurological Disease Metabolic Disease
Anisotropine (Octatropine) bromide is an orally active anticholinergic muscarinic antagonist. Anisotropine bromide can inhibit gastric acid secretion and is used as an adjunct to peptic ulcers .

HY-17037A

Pirenzepine LS 519 free base; Pirenzepin; Gastrozepin	mAChR	Metabolic Disease Cancer
Pirenzepine (LS 519 free base) is a selective M1 mAChR (muscarinic acetylcholine receptor) antagonist. Pirenzepine reduces gastric acid secretion and reduces muscle spasm, can be used in peptic ulcers research. Pirenzepine shows anti-proliferative activity to cancer cells .

HY-W003467

Rabeprazole Sulfide	Proton Pump Bacterial	Infection Inflammation/Immunology
Rabeprazole Sulfide is an active metabolite of Rabeprazole. Rabeprazole is a proton pump inhibitor that suppresses gastric acid secretion through an interaction with (H ⁺/K ⁺)-ATPase in gastric parietal cells. Rabeprazole markedly inhibits the motility of *H. pylori. Rabeprazole has the potential for various peptic* diseases treatment .

HY-145578

Linaprazan glurate X842	Others	Inflammation/Immunology
Linaprazan glurate inhibits exogenously or endogenously stimulated gastric acid secretion. Linaprazan glurate exhibits several advantageous properties, such as fast onset, high in vivo potency and/or long duration of action. Linaprazan glurate is useful in the research of gastrointestinal inflammatory diseases and peptic ulcer diseases (extracted from patent WO2010063876A1) .

HY-W003467R

Rabeprazole Sulfide (Standard)	Proton Pump Bacterial	Infection Inflammation/Immunology
Rabeprazole Sulfide (Standard) is the analytical standard of Rabeprazole Sulfide. This product is intended for research and analytical applications. Rabeprazole Sulfide is an active metabolite of Rabeprazole. Rabeprazole is a proton pump inhibitor that suppresses gastric acid secretion through an interaction with (H ⁺/K ⁺)-ATPase in gastric parietal cells. Rabeprazole markedly inhibits the motility of *H. pylori. Rabeprazole has the potential for various peptic* diseases treatment .

HY-B0377G

Famotidine (GMP) MK-208 (GMP)	Histamine Receptor	Inflammation/Immunology Cancer
Famotidine GMP (MK-208 GMP) is Famotidine (HY-B0377) produced in GMP guideline. Famotidine GMP is a competitive histamine H2-receptor antagonist, inhibits gastric secretion, activates the gastric mucosal defensive mechanisms. Famotidine GMP ameliorates peptic ulcer disease (PUD) and gastroesophageal reflux disease (GERD/GORD) in rats model .

HY-17037S1

Pirenzepine-d8 dihydrochloride LS 519-d₈ dihydrochloride; Pirenzepin-d₈ dihydrochloride; Gastrozepin-d₈ dihydrochloride	Isotope-Labeled Compounds	Cancer
Pirenzepine-d₈ (LS 519-d₈; Pirenzepin-d₈) dihydrochloride is a deuterium labeled Pirenzepine (dihydrochloride) (HY-17037). Pirenzepine (LS 519) dihydrochloride is a selective M1 mAChR (muscarinic acetylcholine receptor) antagonist. Pirenzepine dihydrochloride reduces gastric acid secretion and reduces muscle spasm, can be used in peptic ulcers research. Pirenzepine dihydrochloride shows anti-proliferative activity to cancer cells .

HY-15295

Vonoprazan Fumarate 4 Publications Verification TAK-438	Proton Pump	Metabolic Disease
Vonoprazan Fumarate (TAK-438), a proton pump inhibitor (PPI), is a potent and orally active potassium-competitive acid blocker (P-CAB), with antisecretory activity. Vonoprazan Fumarate inhibits H ⁺,K ⁺-ATPase activity in porcine gastric microsomes with an IC₅₀ of 19 nM at pH 6.5. Vonoprazan Fumarate is developed for the research of acid-related diseases, such as gastroesophageal reflux disease and peptic ulcer disease .

HY-100007

Vonoprazan 4 Publications Verification TAK-438 free base	Proton Pump Bacterial	Endocrinology
Vonoprazan (TAK-438 free base), a proton pump inhibitor (PPI), is a potent and orally active potassium-competitive acid blocker (P-CAB), with antisecretory activity. Vonoprazan inhibits H ⁺,K ⁺-ATPase activity in porcine gastric microsomes with an IC₅₀ of 19 nM at pH 6.5. Vonoprazan is developed for the research of acid-related diseases, such as gastroesophageal reflux disease and peptic ulcer disease. Vonoprazan can be used for eradication of Helicobacter pylori .

HY-100007A

Vonoprazan hydrochloride TAK-438 hydrochloride	Proton Pump Bacterial	Infection Endocrinology
Vonoprazan hydrochloride, a proton pump inhibitor (PPI), is a potent and orally active potassium-competitive acid blocker (P-CAB), with antisecretory activity. Vonoprazan hydrochloride inhibits H ⁺,K ⁺-ATPase activity in porcine gastric microsomes with an IC₅₀ of 19 nM at pH 6.5. Vonoprazan hydrochloride is developed for the research of acid-related diseases, such as gastroesophageal reflux disease and peptic ulcer disease. Vonoprazan hydrochloride can be used for eradication of Helicobacter pylori .

HY-100007R

Vonoprazan (Standard) TAK-438 (Standard)	Proton Pump Bacterial	Endocrinology
Vonoprazan (Standard) is the analytical standard of Vonoprazan. This product is intended for research and analytical applications. Vonoprazan (TAK-438 free base), a proton pump inhibitor (PPI), is a potent and orally active potassium-competitive acid blocker (P-CAB), with antisecretory activity. Vonoprazan inhibits H ⁺,K ⁺-ATPase activity in porcine gastric microsomes with an IC₅₀ of 19 nM at pH 6.5. Vonoprazan is developed for the research of acid-related diseases, such as gastroesophageal reflux disease and peptic ulcer disease. Vonoprazan can be used for eradication of Helicobacter pylori .

Cat. No.	Product Name	Type

HY-B0377G

Famotidine (GMP) MK-208 (GMP)	Fluorescent Dye
Famotidine GMP (MK-208 GMP) is Famotidine (HY-B0377) produced in GMP guideline. Famotidine GMP is a competitive histamine H2-receptor antagonist, inhibits gastric secretion, activates the gastric mucosal defensive mechanisms. Famotidine GMP ameliorates peptic ulcer disease (PUD) and gastroesophageal reflux disease (GERD/GORD) in rats model .

Cat. No.	Product Name	Type

HY-B0377G

Famotidine (GMP) MK-208 (GMP)	Biochemical Assay Reagents
Famotidine GMP (MK-208 GMP) is Famotidine (HY-B0377) produced in GMP guideline. Famotidine GMP is a competitive histamine H2-receptor antagonist, inhibits gastric secretion, activates the gastric mucosal defensive mechanisms. Famotidine GMP ameliorates peptic ulcer disease (PUD) and gastroesophageal reflux disease (GERD/GORD) in rats model .

Cat. No.	Product Name	Chemical Structure

HY-17037S1

Pirenzepine-d8 dihydrochloride
Pirenzepine-d₈ (LS 519-d₈; Pirenzepin-d₈) dihydrochloride is a deuterium labeled Pirenzepine (dihydrochloride) (HY-17037). Pirenzepine (LS 519) dihydrochloride is a selective M1 mAChR (muscarinic acetylcholine receptor) antagonist. Pirenzepine dihydrochloride reduces gastric acid secretion and reduces muscle spasm, can be used in peptic ulcers research. Pirenzepine dihydrochloride shows anti-proliferative activity to cancer cells .

Pirenzepine-d8 dihydrochloride

Pirenzepine-d₈ (LS 519-d₈; Pirenzepin-d₈) dihydrochloride is a deuterium labeled Pirenzepine (dihydrochloride) (HY-17037). Pirenzepine (LS 519) dihydrochloride is a selective M1 mAChR (muscarinic acetylcholine receptor) antagonist. Pirenzepine dihydrochloride reduces gastric acid secretion and reduces muscle spasm, can be used in peptic ulcers research. Pirenzepine dihydrochloride shows anti-proliferative activity to cancer cells .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.